Early Experience with Modified Dose Nirmatrelvir/Ritonavir in Dialysis Patients with Coronavirus Disease 2019.

Swapnil HiremathPeter G BlakeAngie YeungMichaeline McGuintyDoneal ThomasJane IpPierre Antoine BrownMichael PandesAndrew BurkeQazi Zain SohailKaren ToLindsay BlackwellMatthew J OliverArsh K JainZain ChaglaRebecca Cooper

Published in: Clinical journal of the American Society of Nephrology : CJASN (2023)

A modified dose of nirmatrelvir/ritonavir use was found to be safe and well tolerated, with no serious adverse events being observed in a small sample of maintenance dialysis patients.

Keyphrases

end stage renal disease
chronic kidney disease
peritoneal dialysis
coronavirus disease
ejection fraction
newly diagnosed
prognostic factors
antiretroviral therapy
patient reported outcomes